keyword
https://read.qxmd.com/read/38353836/cardamonin-loaded-liposomal-formulation-for-improving-percutaneous-penetration-and-follicular-delivery-for-androgenetic-alopecia
#21
JOURNAL ARTICLE
Zhenda Liu, Zehui He, Xinyi Ai, Teng Guo, Nianping Feng
Androgenic alopecia (AGA) has a considerable impact on the physical and mental health of patients. Nano preparations have apparent advantages and high feasibility in the treatment of AGA. Cardamonin (CAR) has a wide range of pharmacological activities, but it has the problems of poor solubility in water and low bioavailability. There are few, if any, researches on the use of nano-loaded CAR to improve topical skin delivery of AGA. In this study, a CAR-loaded liposomal formulation (CAR@Lip and CAR@Lip Gel) was developed and characterized...
February 14, 2024: Drug Delivery and Translational Research
https://read.qxmd.com/read/38352219/autologous-stem-cell-derived-therapies-for-androgenetic-alopecia-a-systematic-review-of-randomized-control-trials-on-efficacy-safety-and-outcomes
#22
JOURNAL ARTICLE
Konstantinos Gasteratos, Konstantinos Kouzounis, Jeremy Goverman
BACKGROUND: Androgenic alopecia (AGA), a prevalent and extensively studied condition characterized by hair loss, presents a significant global issue for both men and women. Stem cell therapy has emerged as a promising therapeutic approach for AGA due to its regenerative and immunomodulatory properties. The primary objective of this systematic review was to assess the current literature on the efficacy and safety of cellular and acellular stem cell-derived therapies in the management of AGA...
February 2024: Plastic and Reconstructive Surgery. Global Open
https://read.qxmd.com/read/38348763/observing-the-clinical-efficacy-of-combined-serum-microneedle-therapy-for-moderate-to-severe-androgenetic-alopecia-in-scalp-repair
#23
JOURNAL ARTICLE
Fan Zhang, Shutong Jia, Bo Ye, Fenfen Li, Jiayu Zhang, Qiuzi Jin, Man Li
OBJECTIVE: In this study, the safety and efficacy of scalp repair serum microneedles combined with oral drug administration and topical medication were investigated for the treatment of moderate to severe androgenetic alopecia. METHODS: Twenty patients, consisting of 4 males and 16 females, who sought treatment for moderate to severe androgenetic alopecia at our hair medicine research center alopecia specialty clinic between August and December 2022 were randomly selected for the study...
February 2024: Skin Research and Technology
https://read.qxmd.com/read/38336246/recomendaciones-sobre-el-manejo-cl%C3%A3-nico-de-la-alopecia-androg%C3%A3-nica-un-documento-de-consenso-del-grupo-espa%C3%A3-ol-de-tricolog%C3%A3-a-de-la-academia-espa%C3%A3-ola-de-dermatolog%C3%A3-a-y-venereolog%C3%A3-a
#24
S Vañó Galván, P Fernandez Crehuet, G Garnacho, A Gómez Zubiaur, A Hermosa Gelbard, O M Moreno-Arrones, D Saceda Corralo, C Serrano
Androgenetic alopecia can be challenging to treat due to the wide range of available treatments, most of which are not based on evidence from clinical trials. In addition many of the options do not include androgenetic alopecia among the approved indications according to their summaries of product characteristics. A panel of 34 dermatologists from the Spanish Trichology Society of the Spanish Association of Dermatology and Venereology (AEDV) used the Delphi method to develop a consensus statement on the management of androgenetic alopecia...
February 7, 2024: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/38321615/long-term-efficacy-and-safety-of-dutasteride-0-5%C3%A2-mg-in-korean-men-with-androgenetic-alopecia-5-year-data-demonstrating-clinical-improvement-with-sustained-efficacy
#25
JOURNAL ARTICLE
Sangmin Choi, Soon-Hyo Kwon, Woo-Young Sim, Bark-Lynn Lew
Dutasteride 0.5 mg is a dual inhibitor of 5α-reductase type I and II and was approved in Korea in 2009 for treating androgenetic alopecia (AGA) in men. We investigated the 5-year efficacy and safety of dutasteride 0.5 mg in Korean men with AGA using the basic and specific (BASP) classification. This retrospective analysis included 99 male AGA patients aged ≥18 years who were treated with dutasteride 0.5 mg for at least 5 years from October 2009 to December 2016 at Kyung Hee University Hospital in Gangdong...
February 6, 2024: Journal of Dermatology
https://read.qxmd.com/read/38318584/study-of-association-of-dyslipidemia-in-male-androgenetic-alopecia-patients-in-a-tertiary-care-hospital
#26
JOURNAL ARTICLE
Harshatha Sathyanarayanan, Murugan Sundaram
INTRODUCTION: Androgenetic alopecia (AGA) is a hereditary and androgen-dependent progressive thinning of the scalp hair in a defined pattern. Several studies have reported an association between dyslipidemia and AGA. However, scarce data is available on association between severity of AGA and dyslipidemia. Hence, we performed a study to assess the clinical, epidemiological profile in male AGA patients and to compare lipid parameters among AGA cases and non-AGA controls to evaluate dyslipidemia association...
January 2024: Curēus
https://read.qxmd.com/read/38315101/efficacy-and-safety-of-low-dose-oral-minoxidil-in-the-management-of-androgenetic-alopecia
#27
REVIEW
Aditya K Gupta, Mesbah Talukder, Avner Shemer
INTRODUCTION: Treating alopecia can be challenging. The available treatments are topical minoxidil, low-dose oral minoxidil (LDOM), and 5-α reductase inhibitors like finasteride and dutasteride. Only topical minoxidil and finasteride 1 mg daily are FDA-approved, while the rest are used off-label. Recent research has suggested that oral minoxidil may be a safe and effective treatment for both female androgenetic alopecia (female AGA) and male androgenetic alopecia (male AGA)...
February 5, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38313574/increased-interest-in-oral-minoxidil-for-hair-loss-treatment-following-publication-of-august-2022-new-york-times-article-a-google-trends-analysis
#28
JOURNAL ARTICLE
Noelle Desir, Amar D Desai, Shari R Lipner
INTRODUCTION: Androgenetic alopecia (AGA) is the most common form of hair loss, with negative impact on patient quality of life. Oral minoxidil is used off-label for AGA treatment. We hypothesized increased public interest in oral minoxidil for hair loss treatment following the New York Times (NYT) Article on oral minoxidil: "An Old Medicine Grows New Hair for Pennies a Day, Doctors Say." The objective of this study was to quantify interest in oral minoxidil for hair loss treatment before and after the NYT article and help inform dermatologists about treatments of interest to their patients...
February 2024: Skin Appendage Disorders
https://read.qxmd.com/read/38313570/hair-to-hair-trichoscopy-an-objective-method-to-assess-effectiveness-of-botulinum-toxin-in-a-clinical-trial-for-androgenetic-alopecia
#29
JOURNAL ARTICLE
Daniel Fernandes Melo, André Luiz Vairo Donda, Rita Fernanda Cortez de Almeida, Daniela Alves Pereira Antelo, Paulo Muller-Ramos, Carla Jorge Machado, Sidney Frattini, Antonella Tosti, Carlos Baptista Barcaui
INTRODUCTION: Androgenetic alopecia (AGA) is the most common alopecia affecting both genders leading to a potential decrease in quality of life and self-esteem. A current concern in trichology is how to accurately measure clinical response in both daily medical practice and academic research. Hair-to-hair (H2H)-matching technology™ has recently emerged as a technique to evaluate variations in follicular units, hair shaft number, and thickness. This study aimed to describe the methodology employed in a clinical trial using this technology to test the efficacy of botulinum toxin (BT) for male AGA...
February 2024: Skin Appendage Disorders
https://read.qxmd.com/read/38311145/biomimetic-biphasic-microsphere-preparation-based-on-the-thermodynamic-incompatibility-of-glycosaminoglycan-with-gelatin-methacrylate-for-hair-regeneration
#30
JOURNAL ARTICLE
Yangpeng Chen, Danlan Fu, Xiaoqi Wu, Yufan Zhang, Yuxin Chen, Yi Zhou, Mujun Lu, Qifa Liu, Junfei Huang
Hair follicle (HF) tissue engineering is promising for hair loss treatment especially for androgenetic alopecia. Physiologically, the initiation of HF morphogenesis relies on the interactions between hair germ mesenchymal and epithelial layers. To simulate this intricate process, in this study, a co-flowing microfluidic-assisted technology was developed to produce dual aqueous microdroplets capturing growth factors and double-layer cells for subsequent use in hair regeneration. Microspheres, called G/HAD, were generated using glycosaminoglycan-based photo-crosslinkable biological macromolecule (HAD) shells and gelatin methacrylate (GelMA) cores to enclose mesenchymal cells (MSCs) and mouse epidermal cells (EPCs)...
February 2, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38306622/extemporaneous-topical-minoxidil-solutions-for-the-treatment-of-androgenetic-alopecia-stability-studies-and-incorporation-tests-of-active-pharmaceutical-ingredients-in-aloplus-total-base
#31
JOURNAL ARTICLE
Antonio Spennacchio, Angela Assunta Lopedota, Antonio Lopalco, Annalisa Cutrignelli, Flavia Maria la Forgia, Sergio Fontana, Massimo Franco, Nunzio Denora
Minoxidil is one of the most employed active pharmaceutical ingredients for the  treatment of androgenetic alopecia. The authors propose a new method for production of minoxidil lotions using Aloplus Total. The latter is a propylene glycol-free liquid base in which the presence of hydroxypropyl-ß-cyclodextrin and ethanol allows the solubilization of high drug amounts. Minoxidil intrinsic solubility in the base was determined, and a comprehensive chemical and physical stability study was conducted on 8% w/w minoxidil lotions...
2024: International Journal of Pharmaceutical Compounding
https://read.qxmd.com/read/38298748/novel-application-of-1064-nm-picosecond-nd-yag-laser-for-male-androgenetic-alopecia-treatment
#32
JOURNAL ARTICLE
Suparuj Lueangarun, Therdpong Tempark
BACKGROUND: There are limitations and side effects of currently approved treatments for AGA, such as topical minoxidil, oral finasteride, and low-level light therapy. OBJECTIVE: This study aimed to investigate the potential of fractional picosecond laser (FPL) therapy for promoting hair regrowth. METHODS: This was a pilot study in which five male participants were treated with a 1064-nm FPL for mild-to-moderate AGA. The patients underwent three treatments at four-week intervals, followed by a four-week post-procedure assessment...
January 2024: Journal of Clinical and Aesthetic Dermatology
https://read.qxmd.com/read/38293734/therapeutic-maintenance-effect-of-finasteride-1%C3%A2-mg-every-other-month-regimen-in-androgenetic-alopecia-and-study-on-the-difference-in-response-to-finasteride-treatment-a-prospective-cohort-study
#33
JOURNAL ARTICLE
Ki-Hun Kim, Soon-Hyo Kwon, Woo-Young Sim, Bark-Lynn Lew
Finasteride is commonly used for androgenetic alopecia (AGA) treatment. The aim of this study was to assess the therapeutic maintenance effect of a finasteride every other month (EOM) regimen and analyze clinical and laboratory differences in patients with AGA according to their treatment response. One hundred males with AGA who received finasteride 1 mg daily treatment for a year were enrolled in the study. At 1 year follow-up, treatment responses of patients who completed the visit schedule were assessed using five scales...
January 31, 2024: Journal of Dermatology
https://read.qxmd.com/read/38293167/uncovering-the-genetic-architecture-and-evolutionary-roots-of-androgenetic-alopecia-in-african-men
#34
Rohini Janivara, Ujani Hazra, Aaron Pfennig, Maxine Harlemon, Michelle S Kim, Muthukrishnan Eaaswarkhanth, Wenlong C Chen, Adebola Ogunbiyi, Paidamoyo Kachambwa, Lindsay N Petersen, Mohamed Jalloh, James E Mensah, Andrew A Adjei, Ben Adusei, Maureen Joffe, Serigne M Gueye, Oseremen I Aisuodionoe-Shadrach, Pedro W Fernandez, Thomas E Rohan, Caroline Andrews, Timothy R Rebbeck, Akindele O Adebiyi, Ilir Agalliu, Joseph Lachance
Androgenetic alopecia is a highly heritable trait. However, much of our understanding about the genetics of male pattern baldness comes from individuals of European descent. Here, we examined a novel dataset comprising 2,136 men from Ghana, Nigeria, Senegal, and South Africa that were genotyped using a custom array. We first tested how genetic predictions of baldness generalize from Europe to Africa, finding that polygenic scores from European GWAS yielded AUC statistics that ranged from 0.513 to 0.546, indicating that genetic predictions of baldness in African populations performed notably worse than in European populations...
January 15, 2024: bioRxiv
https://read.qxmd.com/read/38286898/botulinum-toxin-type-a-alleviates-androgenetic-alopecia-by-inhibiting-apoptosis-of-dermal-papilla-cells-via-targeting-circ_0135062-mir-506-3p-bax-axis
#35
JOURNAL ARTICLE
Wuhan Wei, Guoxiang Zhao, Qiang Li, Jingyu Zhang, Hanxiao Wei, Caiqi Shen, Bingkun Zhao, Zhe Ji, Linna Wang, Yanping Guo, Peisheng Jin
Botulinum toxin type A (BTXA) has the potential to treat androgenetic alopecia (AGA); however, its impact on the apoptosis of dermal papillary cells (DPCs) is not yet fully understood. Noncoding RNAs play a crucial role in AGA. In this study, we investigated the potential mechanism by which BTXA alleviates apoptosis induced by dihydrotestosterone (DHT) in DPCs. We assessed the mRNA levels of circ_0135062, miR-506-3p, and Bax using qRT-PCR. Binding interactions were analyzed using RNA pulldown and dual-luciferase assays...
January 29, 2024: Aesthetic Plastic Surgery
https://read.qxmd.com/read/38284294/the-role-of-platelet-rich-plasma-in-androgenetic-alopecia-a-systematic-review
#36
REVIEW
C Donnelly, I Minty, A Dsouza, Y Y Wong, I Mukhopadhyay, V Nagarajan, R Rupra, W N Charles, A Khajuria
BACKGROUND: Androgenetic alopecia (AGA), also referred to as male or female pattern hair loss, is the commonest cause of chronic hair loss and affects up to 80% of men by the age of 70. Despite a high prevalence, there are few approved therapies, which show minimal efficacy. OBJECTIVES: This systematic review aims to evaluate the efficacy of platelet-rich plasma (PrP) in the treatment of AGA in male patients. METHODS: MEDLINE, EMBASE, Cochrane (CENTRAL), CINAHL, clinicaltrials...
January 29, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38255258/short-term-clinical-assessment-of-treating-female-androgenetic-alopecia-with-autologous-stem-cells-derived-from-human-hair-follicles
#37
JOURNAL ARTICLE
Katarzyna Krefft-Trzciniecka, Zuzanna Piętowska, Alicja Pakiet, Danuta Nowicka, Jacek C Szepietowski
BACKGROUND: Androgenetic alopecia (AGA) is the most common form of alopecia, but treatment options are limited. This study evaluated clinical improvement in hair condition in women with AGA six months after a single injection of autologous cell micrografts (ACMs) containing hair follicle stem cells and dermal papilla cells. METHODS: Twenty-three women with clinically and dermoscopy-confirmed AGA were included. Five 2.5 mm punch biopsies were taken from the skin of each patient with the Regenera device...
January 11, 2024: Biomedicines
https://read.qxmd.com/read/38247260/investigator-blinded-controlled-and-randomized-comparative-study-on-1565%C3%A2-nm-non-ablative-fractional-laser-versus-5-minoxidil-for-treatment-of-androgenetic-alopecia
#38
JOURNAL ARTICLE
Huanhuan Qu, Rongli Zhang, Wuyan Xin, Huan Jing, Gang Wang, Lin Gao
BACKGROUND: Characterized by progressive hair loss due to an excessive response to androgens, androgenetic alopecia (AGA) affects up to 50% of males and females. Minoxidil is one of approved medications for AGA but inadequate responses occur in many patients. AIMS: To determine whether 1565 nm non-ablative fractional laser (NAFL) could yield better therapeutic benefits for patients with AGA as compared with 5% minoxidil. METHODS: Thirty patients with AGA were enrolled; they were randomly assigned into the laser or minoxidil treatment groups...
January 21, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38239003/efficacy-and-safety-of-combined-microneedling-therapy-for-androgenic-alopecia-a-systematic-review-and-meta-analysis-of%C3%A2-randomized-clinical-trials
#39
REVIEW
Danning Pei, Linxi Zeng, Xin Huang, Bin Wang, Lu Liu, Guoqiang Zhang
OBJECTIVE: To provide dermatologists with more clinical experience in treating androgenetic alopecia, we evaluated the effect and safety of combined microneedling therapy for androgenetic alopecia. METHODS: Studies on combined microneedling for hair loss were comprehensively searched by us in PubMed, Excerpta Medica Database, and the Cochrane Library Database. The literature search spanned the period from 2012 to 2022. Inclusion and exclusion criteria were developed, and the literature was screened according to this criteria...
January 18, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38206135/oral-minoxidil-media-coverage-the-impact-on-patient-perceptions-and-practitioner-approaches-to-androgenetic-alopecia
#40
JOURNAL ARTICLE
Sapana Desai, Eric Sanfilippo, Adam Friedman
No abstract text is available yet for this article.
January 1, 2024: Journal of Drugs in Dermatology: JDD
keyword
keyword
28037
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.